TransMedics Group (TMDX) Stock Statistics & Valuation Metrics

TransMedics Group has a market cap or net worth of $3.56B. The enterprise value is $4.12B.

TransMedics Group has 33,833,790 shares outstanding. The number of shares has decreased by -2.65% in one year.

TransMedics Group’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 4.98%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, TransMedics Group had revenue of 441.54M and earned 35.46M in profits. Earnings per share was 1.07.

In the last 12 months, operating cash flow was 49.38M and capital expenditures -112.61M, giving a free cash flow of -63.23M billion.

TransMedics Group pays an annual dividend of ―, resulting in a dividend yield of ―

TransMedics Group upcoming earnings date is Nov 11, 2025, After Close (Confirmed).

TransMedics Group as a current ratio of 8.30, with Debt / Equity ratio of 194.67%

In the past 12 months, TransMedics Group has paid 316.00K in taxes.

TransMedics Group EV to EBITDA ratio is 32.22, with an EV/FCF ratio of -27.84.

TransMedics Group has $310.14M in cash and marketable securities with $518.41M in debt, giving a net cash position of $208.27M billion.

Gross margin is 59.45%, with operating margin of 8.49%, and net profit margin of 8.03%.

The average price target for TransMedics Group is $140.57, which is 11.43% higher than the current price. The consensus rating is Moderate Buy